



Resolution n°19-2025-e

“Accelerating tools to drive tuberculosis detection (Phase 2)” Project (“DRIVEDX4TB TOO”)

Acknowledging that Unitaid’s investments in the Seq&Treat project, commencing in 2019, and the DriveDx4TB project, commencing in 2022 (“the TB Diagnostic Investments”), have formed the cornerstone of Unitaid’s recent contribution and leadership to closing the TB diagnostic gap; and acknowledging the opportunity to build on the achievements of the TB Diagnostic Investments through the implementation of the remaining outputs and activities.

Recalling Resolution EB45/2024/R5 in which the Executive Board requested the Secretariat to propose existing Unitaid lead implementers with the capacity and willingness to implement the remaining outputs and activities foreseen within the TB Diagnostic Investments, subject to confirmation by the Secretariat of the ongoing strategic importance and high chance of success.

Acknowledging the proposal submitted at the Secretariat’s invitation by Aurum for the implementation of a project integrating outputs and activities foreseen within the TB Diagnostic Investments, entitled: “Accelerating tools to drive tuberculosis detection (Phase 2)” (the “Project”);

Noting the recommendations of the Secretariat and the Proposal Review Committee, the Executive Board authorizes the Executive Director to commit up to USD 11.8 million for the Project, subject to availability of funds.

Funding is conditional upon signature of a legal agreement between Unitaid and Aurum.

Lead Organization: Aurum

Project Duration: 4 years 6 months

A handwritten signature in blue ink, appearing to read "Marisol Touraine", with a horizontal line underneath.

Marisol Touraine
Chair of the Executive Board

Date: 2 June 2025